The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combined targeting of LSD1 (KDM1A) and histone deacetylases exerts superior efficacy against human AML.
Warren Fiskus
No relevant relationships to disclose
Sunil Sharma
Employment or Leadership Position - Beta Cat Pharmaceuticals (U)
Stock Ownership - Beta Cat Pharmaceuticals
Research Funding - Beta Cat Pharmaceuticals
Rekha Rao
No relevant relationships to disclose
Ramesh Balusu
No relevant relationships to disclose
Sreedhar Venkannagari
No relevant relationships to disclose
Siddhartha Ganguly
No relevant relationships to disclose
David Bearss
Stock Ownership - Salarius Pharmaceuticals
Kapil N. Bhalla
Consultant or Advisory Role - Beta Cat Pharmaceuticals (U)
Research Funding - Novartis